title: Invited commentary: Biological and clinical insights from epidemiologic research into HIV, HPV, and anal cancer.
abstract: Anal cancer is common among people infected with human immunodeficiency virus (HIV). This cancer is caused by human papillomavirus, and immunosuppression likely contributes to its development. In this issue of the Journal, Bertisch et al. (Am J Epidemiol. 2013;178(6):877-884) present the results of a case-control study of anal cancer among HIV-infected people in Switzerland. They demonstrate that anal cancer risk is increased in association with a low CD4+ cell count (a clinical measurement of immune status). In particular, HIV-induced immunosuppression was most severe among cases approximately 6-7 years prior to the diagnosis of anal cancer. A plausible biological interpretation is that immunosuppression is important at an early stage of the development of anal cancer, but that the neoplastic process becomes irreversible over time with persistent human papillomavirus infection and genetic damage. With current efforts to provide earlier combination antiretroviral therapy to HIV-infected people, anal cancer incidence may start to decline. Bertisch et al. also demonstrate a strong association between serum antibodies against the human papillomavirus type 16 protein E6 and anal cancer risk, highlighting the role of this viral oncoprotein in carcinogenesis. Additional biomarkers could help refine clinical approaches to anal cancer screening and prevention for the HIV-infected population.
authors.forename: Eric A
authors.initials: EA
authors.lastname: Engels
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Madeleine
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data*; D001005:Anus Neoplasms / Q000209:etiology*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000150:complications*; D012907:Smoking / Q000009:adverse effects*; D015819:Substance Abuse, Intravenous / Q000150:complications*
keywords: acquired immunodeficiency syndrome; anal cancer; combination antiretroviral therapy; human immunodeficiency virus; human papillomavirus; immunosuppression; screening
references.citation: Cancer Res. 2001 Mar 1;61(5):1934-40
references.pmid: 11280749
references.citation: J Natl Cancer Inst. 2011 May 4;103(9):753-62
references.pmid: 21483021
references.citation: Lancet Oncol. 2012 May;13(5):487-500
references.pmid: 22445259
references.citation: Int J Cancer. 1993 Nov 11;55(5):780-4
references.pmid: 8244575
references.citation: J Natl Cancer Inst. 2012 Oct 17;104(20):1591-8
references.pmid: 23042932
references.citation: N Engl J Med. 2013 Mar 7;368(10):886-9
references.pmid: 23425131
references.citation: Lancet Oncol. 2009 Dec;10(12):1152-9
references.pmid: 19818686
references.citation: JAMA. 2012 Jul 25;308(4):387-402
references.pmid: 22820792
references.citation: JAMA. 1999 May 19;281(19):1822-9
references.pmid: 10340370
references.citation: Cancer Res. 2010 Nov 1;70(21):8388-97
references.pmid: 20959478
references.citation: Lancet Oncol. 2012 May;13(5):438-40
references.pmid: 22445258
references.citation: Lancet. 2007 Jul 7;370(9581):59-67
references.pmid: 17617273
references.citation: AIDS. 2006 Aug 1;20(12):1645-54
references.pmid: 16868446
references.citation: Cancer. 2004 Jul 15;101(2):270-80
references.pmid: 15241823
references.citation: J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30
references.pmid: 19648510
references.citation: Ann Intern Med. 2008 May 20;148(10):728-36
references.pmid: 18490686
references.citation: Am J Epidemiol. 2013 Sep 15;178(6):877-84
references.pmid: 23900553